Torre L A,Bray F,Siegel R L, et al. Global cancer statistics,2012 [J]. CA Cancer J Clin,2015,65(2):87-108.
[2]
De Martel C, Plummer M, Vignat J, et al. Worldwide burden of cancer attributable to HPV by site, country and HPV type [J]. Int J Cancer, 2017, 141(4): 664-670.
[3]
Chesson H W, Dunne E F, Hariri S, et al. The estimated lifetime probability of acquiring human papillomavirus in the United States[J]. Sex Transm Dis, 2014, 41(11): 660-664.
[4]
Garland S M, Kjaer S K, Muñoz N. Impact and effectiveness of the quadrivalent human papillomavirus vaccine: a systematic review of 10 years of real-world experience[J]. Clin Infect Dis, 2016, 63(4): 519-527.
[5]
Forman D,de Martel C,Lacey CJ,et al.Global burden of human papillomavirus and related diseases[J]. Vaccine, 2012, 30 Suppl 5:F12-23.
[6]
Naud P S, Roteli Martins C M, De Carvalho N S, et al. Sustained efficacy, immunogenicity and safety of the HPV-16/18 S04-adjuvanted vaccine: final analysis of a long-term follow-up study up to 9.4 years post-vaccination [J]. Hum Vaccin Immunother, 2014, 10(8): 2147-2162.
[7]
Wheeler C M, Skinner S R, Del Rosario-Raymundo M R, et al. Efficacy, safety, and immunogenicity of the human papillomavirus16/18 AS04-adjuvanted vaccine in women older than 25 years:7-year follow-up of the phase 3, double-blind, randomised controlled VIVIANE study[J]. Lancet Infect Dis, 2016, 16(10):1154-1168.
[8]
Tabrizi S N, Brotherton J M, Kaldor J M. Assessment of herd immunity and cross-protection after a human papillomavirus vaccination programme in Australia: a repeat cross-sectional study [J]. Lancet Infect Dis, 2014, 14(10): 958-966.
[9]
Markowitz L E, Liu G, Hariri S, et al. Prevalence of HPV after introduction of the vaccination program in the United States [J]. Pediatrics, 2016, 137(3): 2015-1968.
[10]
Smith M A, Liu B, McIntyre P, et al. Trends in genital warts by socioeconomic status after the introduction of the national HPV vaccination program in Australia: analysis of national hospital data[J]. BMC Infect Dis, 2016, 16:52.
[11]
Bollerup S, Baldur-Felskov B, Blomberg M, et al. Significant reduction in the incidence of genital warts in young men 5 years into the Danish Human Papillomavirus Vaccination Program for Girls and Women[J]. Sex Transm Dis, 2016, 43(4): 238-242.
[12]
Muñoz N, Kjaer S K, Sigurdsson K, et al. Impact of human papillomavirus (HPV)-6/11/16/18 vaccine on all HPV-associated genital diseases in young women[J]. J Natl Cancer Inst, 2010, 102(5): 325-339.
[13]
Herweijer E, Sundstrom T, Ploner A, et al. Quadrivalent HPV vaccine effectiveness against high-grade cervical lesions by age at vaccination: A population-based study [J]. Int J Cancer, 2016, 138(12): 2867-2874.
[14]
Huh W K, Joura E A, Giuliano A R, et al. Final efficacy, immunogenicity, and safety analyses of a nine-valent humanpapillomavirus vaccine in women aged 16-26 years: a randomized, double-blind trial [J]. Lancet, 2017, 390(10108): 2143-2159.
[15]
Setiawan D, Luttjeboer J, Pouwels K B, et al. Immunogenicity and safety of human papillomavirus (HPV) vaccination in Asian populations from six countries: a meta-analysis[J]. Jpn J Clin Oncol,2017,47(3):265-276.
[16]
Moreira E D, Giuliano A R, De Hoon J, et al. Safety profile of the 9-valent human papillomavirus vaccine: assessment in prior quadrivalent HPV vaccine recipients and in men 16 to 26 years of age [J]. Hum Vaccin Immunother, 2018, 14(2):396-403.
[17]
Bruni L,Diaz M,Barrionuevo-Rosas L,et al.Global estimates of human papillomavirus vaccination coverage by region and income level:A pooled analysis[J].Lancet Glob Health,2016,4(7):e453-463.
[18]
Bhatla N, Suri V, Basu P, et al. Immunogenicity and safety of human papillomavirus-16/18 AS04-adjuvanted cervical cancer vaccine in healthy Indian women[J].J Obstet Gynaecol Res, 2010, 36 (1): 123-132.
[19]
Schwarz T, Spaczynski M, Kaufmann A, et al. Persistence of immune responses to the HPV-16/18 AS04-adjuvanted Vaccine in women aged 15-55 years and first-time modelling of antibody responses in mature women: results from an open-label 6-year follow-up study [J]. BJOG, 2015, 122(1): 107-118.
[20]
Castellsagué X, Muñoz N, Pitisuttithum P, et al. End-of-study safety, immunogenicity, and efficacy of quadrivalent HPV (types 6, 11, 16, 18) recombinant vaccine in adult women 24-45 years of age[J]. Br J Cancer, 2011, 105(1): 28-37.
[21]
Meites E, Kempe A, Markowitz L E. Use of a 2-dose schedule for human papillomavirus vaccination-updated recommendations of the Advisory Committee on Immunization Practices[J]. Am J Transplan,2017,17(3):834-837.
[22]
Einstein, Takacs P, Chatterjee A, et al. Comparison of long-term immunogenicity and safety of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine and HPV-6/11/16/18 vaccine in healthy women aged 18-45 years: end-of-study analysis of a phase Ⅲ randomized trial [J]. Hum Vaccin Immunother, 2014, 10 (12): 3435-3445.
[23]
Nygard M, Saah A, Munk C, et al. Evaluation of the long-term anti-human papillomavirus 6 (HPV6), 11, 16, and 18 immune responses generated by the quadrivalent HPV vaccine[J]. Clin Vaccine Immunol, 2015, 22 (8):943-948.
[24]
Harper D M, DeMars L R. HPV vaccines-a reviewof the first decade [J]. Gynecol Oncol, 2017, 146(1): 196-204.
[25]
Garland S M, Cheung T H, McNeill S, et al. Safety and immunogenicity of a 9-valent HPV vaccine in females 12-26 years of age who previously received the quadrivalent HPV vaccine[J].Vaccine, 2015, 33 (48): 6855-6864.
[26]
Di J, Rutherford S, Chu C. Review of the cervical cancer burden and population-based cervical cancer screening in China [J]. Asian Pac J Cancer Prev,2015, 16(17): 7401-7407.
2019, Vol. 30 
